Identification
NameHuman Serum Albumin
Accession NumberDB00062  (BTD00059, BTD00089, BTD00101, BIOD00059, BIOD00089, BIOD00101, DB00096, DB00064)
TypeBiotech
GroupsApproved
Description

Human serum albumin isolated from expired blood plasma. In the iodonated form ( I 131), it is used as a diagnostic radiopharmaceutical for intravenous imaging.

Protein structureDb00062
Related Articles
Protein chemical formulaC2936H4624N786O889S41
Protein average weight66472.2 Da
Sequences
> Human Serum Albumin Sequence
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL
Download FASTA Format
Synonyms
Albumin (human)
Albumin human
Albumin microspheres, human
Albumin, blood
Albumin, human
Human albumin
Microspheres of human albumin
Serum albumin
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbukedSolution10 g/50mLIntravenousKedrion Biopharma, Inc.1981-07-28Not applicableUs
AlbukedSolution5 g/20mLIntravenousKedrion Biopharma, Inc.1942-10-21Not applicableUs
AlbukedSolution5 g/20mLIntravenousKedrion Biopharma, Inc.1942-10-21Not applicableUs
AlbukedSolution.05 g/mLIntravenousKedrion Biopharma, Inc.1976-08-26Not applicableUs
AlbukedSolution2.5 g/50mLIntravenousKedrion Biopharma, Inc.1976-08-26Not applicableUs
AlbukedSolution10 g/50mLIntravenousKedrion Biopharma, Inc.1981-07-28Not applicableUs
Albumin (human)Solution250 g/1000mLIntravenousOctapharma2006-10-17Not applicableUs
Albumin (human)Solution50 g/1000mLIntravenousOctapharma Pharmazeutika Produktionsgesellschaft M.B.H.2006-10-17Not applicableUs
Albumin (human)Solution50 g/1000mLIntravenousOctapharma2006-10-17Not applicableUs
Albumin (human)Solution200 g/1000mLIntravenousOctapharma Pharmazeutika Produktionsgesellschaft M.B.H.2006-10-17Not applicableUs
Albumin (human)Solution200 g/1000mLIntravenousOctapharma2006-10-17Not applicableUs
Albumin (human)Solution250 g/1000mLIntravenousOctapharma Pharmazeutika Produktionsgesellschaft M.B.H.2006-10-17Not applicableUs
Albumin (human) 25% SolutionSolution25 %IntravenousBaxter Ag1989-10-312008-03-14Canada
Albumin (human) 25% Solution USPSolution25 %IntravenousGrifols Therapeutics Inc.1997-02-10Not applicableCanada
Albumin (human) 5% SolutionSolution5 %IntravenousBaxter Ag1989-12-302008-03-13Canada
Albumin (human) 5% Solution, USPSolution5 %IntravenousGrifols Therapeutics Inc.1997-05-06Not applicableCanada
Albuminar-20Solution20 g/100mLIntravenousCsl Behring2009-01-062016-12-01Us
Albuminar-25Solution25 gIntravenousZlb Behring Llc1985-12-312008-08-27Canada
Albuminar-25Solution25 g/100mLIntravenousCsl Behring2009-01-06Not applicableUs
Albuminar-5Solution2.5 g/50mLIntravenousCsl Behring2009-01-06Not applicableUs
AlbunexSuspension5 %IntravenousTyco Healthcare1998-03-102002-08-07Canada
Alburex - 25Solution25 %IntravenousCsl Behring2007-10-16Not applicableCanada
Alburex - 5Solution5 %IntravenousCsl Behring2008-01-15Not applicableCanada
AlburxSolution12.5 g/250mLIntravenousCsl Behring Ag2009-01-06Not applicableUs
AlburxSolution12.5 g/50mLIntravenousCsl Behring Ag2009-01-06Not applicableUs
AlbuteinInjection, solution10 g/50mLIntravenousGrifols1978-08-15Not applicableUs
AlbuteinInjection, solution12.5 g/50mLIntravenousGrifols1978-08-15Not applicableUs
AlbuteinInjection, solution12.5 g/250mLIntravenousGrifols1978-08-15Not applicableUs
BuminateInjection, solution.05 g/mLIntravenousBaxalta Canada Corporation1955-06-16Not applicableUs
BuminateInjection, solution.25 g/mLIntravenousBaxalta Canada Corporation1954-03-17Not applicableUs
Buminate 25%Solution25 %IntravenousBaxter Laboratories1955-12-312015-02-06Canada
Buminate 5%Solution5 %IntravenousBaxter Laboratories1955-12-312015-02-06Canada
Diluent for Allergenic Extract Sterile Albumin Saline With PhenolLiquid0.03 %Intradermal; SubcutaneousJubilant Hollisterstier Llc1996-12-16Not applicableCanada
FlexbuminSolution.25 g/mLIntravenousBaxalta Canada Corporation2002-08-09Not applicableUs
FlexbuminInjection, solution.05 g/mLIntravenousBaxalta Canada Corporation2014-07-31Not applicableUs
Human Albumin GrifolsSolution10 g/50mLIntravenousGrifols1995-02-17Not applicableUs
Human Albumin GrifolsSolution12.5 g/50mLIntravenousGrifols2003-06-11Not applicableUs
Human Albumin Grifols 20%Solution20 %IntravenousInstituto Grifols, S.A.Not applicableNot applicableCanada
KedbuminInjection, solution12.5 g/50mLIntravenousKedrion S.P.A.2011-09-15Not applicableUs
Normal Serum Albumin Human 25% USPLiquid25 %IntravenousCutter Med & Biol, Division Of Miles Canada Ltd.1951-12-311998-09-25Canada
Octalbin 25%Solution25 %IntravenousOctapharma Pharmazeutika Produktionsges M B H2015-01-06Not applicableCanada
Octalbin 5%Solution5 %IntravenousOctapharma Pharmazeutika Produktionsges M B H2015-01-06Not applicableCanada
OptisonSuspension5 %IntravenousTyco Healthcare2000-06-222003-07-09Canada
PlasbuminSolution2.5 g/50mLIntravenousGrifols1976-08-26Not applicableUs
PlasbuminSolution5 g/20mLIntravenousGrifols1994-09-26Not applicableUs
PlasbuminSolution10 g/50mLIntravenousGrifols1981-07-28Not applicableUs
PlasbuminSolution2.5 g/50mLIntravenousGrifols1994-09-26Not applicableUs
PlasbuminSolution5 g/20mLIntravenousGrifols1942-10-21Not applicableUs
PlasbuminSolution10 g/50mLIntravenousGrifols1994-09-26Not applicableUs
Plasbumin-25Solution250 mgIntravenousGrifols Therapeutics Inc.1997-01-17Not applicableCanada
Plasbumin-5Solution50 mgIntravenousGrifols Therapeutics Inc.1997-01-17Not applicableCanada
PlasmanateSolution2.5 g/50mLIntravenousGrifols1958-10-02Not applicableUs
Sterile Diluent for Allergenic Extract - Albumin Saline With PhenolSolution0.03 %IntravenousAlk Abello, Inc.2007-03-02Not applicableCanada
Sterile Diluent for Allergenic Extracts Normal Saline With HsaLiquid0.03 %Intradermal; SubcutaneousGreer Laboratories2014-02-19Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Albumin Human DiluentOmega Laboratories Ltd
Sterile Diluent for Allergenic ExtractAntigen Laboratories, Inc.
Categories
UNIIZIF514RVZR
CAS number9048-46-8
Pharmacology
Indication

For treatment of severe blood loss, hypervolemia, and hypoproteinemia.

Structured Indications
Pharmacodynamics

Serum albumin is a soluble, monomeric protein necessary for maintaining and regulating the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentration and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.

Mechanism of action

Serum albumin acts as a high molecular weight, very soluble osmolyte. Serum albumin also acts as a protein drug carrier in plasma, and transports hemin, steroids, thyroid hormones and fatty acids. It binds many other substances, such as unconjugated bilirubin, calcium ions, and other fat soluble hormones.

TargetKindPharmacological actionActionsOrganismUniProt ID
Apolipoprotein EProteinunknownNot AvailableHumanP02649 details
Serum amyloid A-1 proteinProteinunknownNot AvailableHumanP0DJI8 details
Protein AMBPProteinunknownNot AvailableHumanP02760 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions No interactions found.
Food InteractionsNot Available
References
Synthesis Reference

Robert A. Tenold, "Preparing essentially monomeric normal human serum albumin." U.S. Patent USRE0362590, issued July, 1976. Rene Fickat, Simon Benita, Francis Puisieux, "Preparation of biodegradable microcapsules based on serum albumin." U.S. Patent US4666641, issued June, 1958.

USRE0362590
General References
  1. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S: Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003 Jul 7;3:6. Epub 2003 Jul 7. [PubMed:12846933 ]
External Links
ATC CodesV08DA01 — Microspheres of human albumin
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticAbdominal Trauma1
1CompletedDiagnosticNeoplasms, Abdominal / Pelvic Neoplasms1
1RecruitingTreatmentCardiomyopathy Due to Anthracyclines1
1TerminatedTreatmentPolyneuropathies1
1TerminatedTreatmentSubarachnoid Hemorrhage1
1, 2Active Not RecruitingDiagnosticVesico-Ureteral Reflux1
1, 2WithdrawnDiagnosticCoronary Artery Disease1
1, 2WithdrawnDiagnosticCrohn's Disease (CD)1
2Active Not RecruitingTreatmentIntermittent Claudication / Peripheral Artery Disease (PAD)1
2CompletedTreatmentAlpha 1-Antitrypsin Deficiency1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnginal Pain / Chronic Ischemic Heart Disease / Ischaemic Cardiomyopathy / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
2CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
2CompletedTreatmentMacular Degeneration1
2CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentSymptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
2RecruitingDiagnosticRenal Cell Adenocarcinoma1
2RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2RecruitingTreatmentChronic Myocardial Ischemia1
2TerminatedDiagnosticCarotid Artery Diseases1
2TerminatedTreatmentCardiopulmonary Bypass / Systemic Inflammatory Response Syndrome (SIRS)1
2, 3Active Not RecruitingTreatmentAllergic Rhinitis (AR)2
2, 3CompletedTreatmentFibrinogen Deficiency in Complex Cardiac Surgery1
2, 3RecruitingTreatmentAlzheimer's Disease (AD)1
2, 3RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2, 3TerminatedTreatmentHypovolaemia1
2, 3Unknown StatusNot AvailableSevere Head Injury1
3CompletedTreatmentLiver Cirrhosis1
3CompletedTreatmentMultifocal Motor Neuropathy (MMN)1
3CompletedTreatmentPolyradiculoneuropathy, Chronic Inflammatory Demyelinating1
3CompletedTreatmentSecondary Recurrent Miscarriage1
3RecruitingTreatmentPostoperative Kidney Injury1
3TerminatedTreatmentAcute Ischemic Stroke (AIS)1
3TerminatedTreatmentAlzheimer's Disease (AD)1
3TerminatedTreatmentLiver Cirrhosis / Renal Failure / Sepsis1
3TerminatedTreatmentLung Injury, Acute (ALI) / Respiratory Distress Syndrome, Acute (ARDS)1
4CompletedNot AvailableEchocardiography1
4CompletedDiagnosticPulmonary Hypertension (PH)1
4CompletedPreventionHemorrhage1
4CompletedPreventionHepatic Encephalopathy1
4CompletedTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
4CompletedTreatmentHeart; Dysfunction Postoperative, Cardiac Surgery1
4CompletedTreatmentHypoalbuminemia / Peptic Ulcer Bleeding1
4Not Yet RecruitingTreatmentHypoalbuminemia / Shock / Systemic Inflammatory Response Syndrome (SIRS)1
4RecruitingDiagnosticNonvalvular Atrial Fibrillation1
4RecruitingDiagnosticTransplantation, Kidney1
4RecruitingTreatmentAlpha-1 Anti-trypsin Deficiency / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentHepatic Encephalopathy / Liver Cirrhosis1
4RecruitingTreatmentHypoalbuminemia1
4TerminatedTreatmentSpontaneous Bacterial Peritonitis (SBP)1
4TerminatedTreatmentMinor burns1
4Unknown StatusTreatmentHemorrhage; Complicating Delivery, Coagulation Defect1
4Unknown StatusTreatmentSecond or Third Degree Burns1
Not AvailableActive Not RecruitingTreatmentLiver Cirrhosis1
Not AvailableCompletedScreeningCancer, Breast1
Not AvailableNot Yet RecruitingNot AvailableHeart Transplantation1
Not AvailableRecruitingDiagnosticTransesophageal Echocardiography Contrast Agents1
Not AvailableRecruitingOtherEndothelial Dysfunction1
Not AvailableRecruitingTreatmentAortic Valve Disorder / Brain Injury / Coronary Heart Disease (CHD) / Renal Failure / Shock, Cardiogenic / Strokes1
Not AvailableRecruitingTreatmentAscites / Liver Cirrhosis1
Not AvailableRecruitingTreatmentHemodynamic Stability1
Not AvailableSuspendedDiagnosticAscites / Liver Cirrhosis1
Not AvailableTerminatedTreatmentSubarachnoid Hemorrhage1
Not AvailableUnknown StatusDiagnosticCoronary Artery Disease / Myocardial Perfusion Abnormalities1
Not AvailableWithdrawnDiagnosticCarotid Stenosis / Coronary Stenosis / Myocardial Reperfusion1
Not AvailableWithdrawnDiagnosticOvarian Hyperstimulation Syndrome1
Not AvailableWithdrawnDiagnosticRenal Cell Adenocarcinoma1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous.05 g/mL
SolutionIntravenous200 g/1000mL
SolutionIntravenous250 g/1000mL
SolutionIntravenous50 g/1000mL
SolutionIntravenous5 %
LiquidSubcutaneous
SolutionIntravenous20 g/100mL
SolutionIntravenous25 g
SolutionIntravenous25 g/100mL
SolutionIntravenous2.5 g/50mL
SuspensionIntravenous5 %
SolutionIntravenous12.5 g/250mL
Injection, solutionIntravenous10 g/50mL
Injection, solutionIntravenous12.5 g/250mL
Injection, solutionIntravenous.05 g/mL
Injection, solutionIntravenous.25 g/mL
LiquidIntradermal; Subcutaneous0.03 %
SolutionIntravenous.25 g/mL
SolutionIntravenous12.5 g/50mL
SolutionIntravenous20 %
Injection, solutionIntravenous12.5 g/50mL
LiquidIntravenous25 %
SolutionIntravenous25 %
SolutionIntravenous10 g/50mL
SolutionIntravenous5 g/20mL
SolutionIntravenous250 mg
SolutionIntravenous50 mg
Injection, solutionIntradermal; Subcutaneous
SolutionIntravenous0.03 %
Prices
Unit descriptionCostUnit
Buminate 25% iv solution2.22USD ml
Albumin 25% iv solution1.97USD ml
Albutein 25% vial1.32USD ml
Buminate 5% iv solution0.44USD ml
Albutein 5% iv solution0.43USD ml
Albumin (human) 5% iv solution0.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5558094 No1995-02-282012-02-28Us
US6723303 No2001-04-202021-04-20Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point (°C)62 °CFlora, K. et al., Biophys J. 75:1084-1096 (1998)
hydrophobicity-0.395Not Available
isoelectric point5.67Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Very-low-density lipoprotein particle receptor binding
Specific Function:
Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
Gene Name:
APOE
Uniprot ID:
P02649
Molecular Weight:
36153.83 Da
References
  1. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K: Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006 Jun;317(3):1246-53. Epub 2006 Mar 22. [PubMed:16554356 ]
  2. Yamashita T, Kawashima S, Hirase T, Shinohara M, Takaya T, Sasaki N, Takeda M, Tawa H, Inoue N, Hirata K, Yokoyama M: Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice. Am J Physiol Cell Physiol. 2007 Sep;293(3):C865-73. Epub 2007 Jun 6. [PubMed:17553935 ]
  3. Yuan ZY, Liu Y, Kishimoto C, Shioji K, Yokode M, Liu ZQ: [The Fc region of immunoglobulin suppresses atherosclerosis in apolipoprotein E knockout mice]. Zhonghua Yi Xue Za Zhi. 2003 Mar 25;83(6):489-93. [PubMed:12887764 ]
  4. Mojzisova H, Bonneau S, Vever-Bizet C, Brault D: The pH-dependent distribution of the photosensitizer chlorin e6 among plasma proteins and membranes: a physico-chemical approach. Biochim Biophys Acta. 2007 Feb;1768(2):366-74. Epub 2006 Oct 25. [PubMed:17141733 ]
  5. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M: Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H899-906. [PubMed:12860569 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Heparin binding
Specific Function:
Major acute phase protein.
Gene Name:
SAA1
Uniprot ID:
P0DJI8
Molecular Weight:
13531.885 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Small molecule binding
Specific Function:
Inter-alpha-trypsin inhibitor inhibits trypsin, plasmin, and lysosomal granulocytic elastase. Inhibits calcium oxalate crystallization.Trypstatin is a trypsin inhibitor.
Gene Name:
AMBP
Uniprot ID:
P02760
Molecular Weight:
38999.215 Da
References
  1. Sala A, Campagnoli M, Perani E, Romano A, Labo S, Monzani E, Minchiotti L, Galliano M: Human alpha-1-microglobulin is covalently bound to kynurenine-derived chromophores. J Biol Chem. 2004 Dec 3;279(49):51033-41. Epub 2004 Sep 27. [PubMed:15452109 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou Q, Matsumoto S, Ding LR, Fischer NE, Inaba T: The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci. 2004 Sep 17;75(18):2145-55. [PubMed:15325841 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Salavej P, Spalteholz H, Arnhold J: Modification of amino acid residues in human serum albumin by myeloperoxidase. Free Radic Biol Med. 2006 Feb 1;40(3):516-25. Epub 2005 Nov 9. [PubMed:16443167 ]
  2. Senthilmohan R, Kettle AJ: Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. Arch Biochem Biophys. 2006 Jan 15;445(2):235-44. Epub 2005 Aug 3. [PubMed:16125131 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Rowland A, Knights KM, Mackenzie PI, Miners JO: The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62. doi: 10.1124/dmd.108.021105. Epub 2008 Mar 24. [PubMed:18362158 ]
Drug created on June 13, 2005 07:24 / Updated on July 23, 2017 12:15